For a hypothetic good manufacturing practice (GMP) production and clinical use of DNAM-1 chimeric receptor-engineered NK cells, primary NK cells should be isolated through leukapheresis by the blood of a HLA-matched unrelated healthy donor, ex vivo expanded and activated, engineered for the expression of DNAM-1 chimeric receptor, expanded to be infused in cancer patients or be cryopreserved for future use (Figure 2). This evidence concerns the gene CD226 and cancer.